MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice.
Alexander H G PatersonPeter C LucasStewart J AndersonEleftherios P MamounasAdam M BrufskyLuis Baez-DiazKaren M KingThomas LadAndré RobidouxMelanie FinniganMiguel SampayoJuan Carlos TerceroJoël Jean MairetAntonio C WolffLouis FehrenbacherNorman WolmarkRoger R GomisPublished in: JNCI cancer spectrum (2021)
Nonamplified MAF showed statistically significant benefits (DFS and OS) with oral clodronate, supporting validation of the AZURE study.